Clinical Trial Detail

NCT ID NCT03699384
Title Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

acute myeloid leukemia

Therapies

Avelumab + Azacitidine

Age Groups: adult senior

No variant requirements are available.